Table 1

Characteristics of the included studies

AuthorsOriginal samplesPatients settingTypes of statinSamples (matched)PSM ratioAge (years)Male (%)CVD (%)T2DM (%)HT (%)Statin useOutcomeAdjustmentNOS
Cariou et al20NRHospitalisedUnknown24491:1N/AN/AN/AN/AN/ARoutine. Continuation unclear28 daysIPTW8
Fan et al152147HospitalisedAtorvastatin (69.9)
Rosuvastatin (29.6)
Pravastatin (0.5%)
5121:16541212051Routine and continued in-hospitalIn-hospitalMultivariable Cox-regression
age, gender, TC, triglyceride, LDL, procalcitonin, BNP
8
Gupta et al122626HospitalisedUnknown12961:17045144768RoutineIn-hospital (30 days)Multivariable logistic regression
age, gender, comorbidities, medications
8
Lee et al1610 448HospitalisedAll15991:26534195771Routine. Continuation unclear60 daysMultivariable Cox-regression age, sex, history of comorbidities8
Oh et al 177780HospitalisedUnknown23331:1N/AN/AN/AN/AN/ARoutine and continued in-hospitalIn-hospitalMultivariable logistic regression
factors unclear
8
Peymani et al18150Outpatients+hospitalisedAtorvastatin (94.7) Rosuvastatin (2.7) Simvastatin
(2.7)
1501:1635922129Routine and continued27 daysMultivariable Cox-regression
factors unclear
8
Saeed et al194252HospitalisedAtorvastatin (76)
Pravastatin (5)
Rosuvastatin (1)
Simvastatin (18)
18021:1N/AN/AN/AN/AN/AIn-hospitalIn-hospitalIPTW9
Zhang et al1313 981HospitalisedAtorvastatin (83.2)
Rosuvastatin (15.6)
43051:4N/AN/AN/AN/AN/AIn-hospital28 daysMultivariable logistic regression
age, gender, and SpO2 at admission
8
  • Age, male, CVD, T2DM and HT refer to the PSM cohort.

  • BNP, brain natriuretic peptide; CVD, cardiovascular diseases; HT, hypertension; IPTW, inverse probability of treatment weighting; LDL, low-density lipoprotein; N/A, not applicable/available; NOS, Newcastle-Ottawa Scale; PSM, propensity-score matching; SpO2, O2 saturation; TC, total cholestrol; T2DM, type 2 diabetes mellitus.